Xinmai Medical: Hector Chest Main Multibranch Stent Receives Breakthrough Device Designation from the U.S. FDA

Xinmai Medical announces that its innovative development, the Hector / Tongtianji Thoracic Aortic Multi-Branch Covered Stent System (Hector Thoracic Main Multi-Branch Stent), received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) on February 27, 2026. This product is used for minimally invasive interventional treatment of thoracic aortic lesions involving the three branches of the aortic arch. (Shanghai Stock Exchange)